CS Group (OTCQB: CSDX) announced the appointment of Shah Teelani & Associates, a Dubai-based Public Company Accounting Oversight Board (PCAOB) registered auditor, to oversee the consolidation and audit of all 2025 financial statements for CS Diagnostics Corp. (CSDX), CS Interpharm GT LLC, and CS Diagnostics Pharma GmbH. This engagement reflects the Group’s commitment to strengthening financial governance, regulatory compliance, and transparency as it advances its international expansion strategy across the United States, GCC region, and Europe.
According to management, appointing a PCAOB-registered audit firm is a significant step in aligning the Group’s financial reporting structure with U.S. public company standards while integrating its growing international subsidiaries under a unified reporting framework. The consolidated audit will support enhanced financial clarity, streamlined reporting processes, and strengthened investor confidence. The 2025 consolidated financial review will encompass operations related to the MEDUSA hygiene and disinfectant platform and international distribution expansion.
“Engaging Shah Teelani & Associates as our PCAOB-registered auditor represents an important milestone in CS Group’s evolution as a publicly traded company,” said Mohammad Essayed, Group Chief Financial Officer. “As we scale operations across multiple regions, it is essential that our financial reporting structure reflects institutional-grade standards, transparency, and regulatory compliance. This appointment strengthens our governance foundation and supports our long-term growth strategy.”
CS Diagnostics Corp. (OTCQB: CSDX) is a medical technology company advancing a dual-focus platform across infection control and oncology, targeting high-priority global healthcare markets. The Company’s portfolio includes MEDUSA, a smart disinfectant and hygiene solutions platform expanding into wet wipes and liquid formulations for institutional and consumer use, and CS Protect-Hydrogel, a tissue spacer designed to protect healthy organs during prostate cancer radiotherapy. CSDX is progressing through key commercialization milestones, including strategic manufacturing partnerships, multi-region launches across the GCC and Europe, diversified B2B and B2C distribution channels, global logistics agreements, and a growing intellectual property and regulatory roadmap.
The Group continues to focus on expanding its manufacturing partnerships, regulatory positioning, international distribution agreements, and capital markets readiness as part of its broader global growth roadmap. Further information is available at https://group-csd.com/.
